Cargando…

Women with Pregnancies Had Lower Adherence to 1% Tenofovir Vaginal Gel as HIV Preexposure Prophylaxis in CAPRISA 004, a Phase IIB Randomized-Controlled Trial

BACKGROUND: Antiretroviral prophylaxis may be a critical strategy to reduce periconception HIV transmission. Maximizing the benefit of periconception pharmacologic HIV risk-reduction requires an understanding of the links between pregnancy and adherence to this prevention strategy. METHODS: We asses...

Descripción completa

Detalles Bibliográficos
Autores principales: Matthews, Lynn T., Sibeko, Sengeziwe, Mansoor, Leila E., Yende-Zuma, Nonhlanhla, Bangsberg, David R., Karim, Quarraisha Abdool
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3589407/
https://www.ncbi.nlm.nih.gov/pubmed/23472071
http://dx.doi.org/10.1371/journal.pone.0056400
_version_ 1782261727142871040
author Matthews, Lynn T.
Sibeko, Sengeziwe
Mansoor, Leila E.
Yende-Zuma, Nonhlanhla
Bangsberg, David R.
Karim, Quarraisha Abdool
author_facet Matthews, Lynn T.
Sibeko, Sengeziwe
Mansoor, Leila E.
Yende-Zuma, Nonhlanhla
Bangsberg, David R.
Karim, Quarraisha Abdool
author_sort Matthews, Lynn T.
collection PubMed
description BACKGROUND: Antiretroviral prophylaxis may be a critical strategy to reduce periconception HIV transmission. Maximizing the benefit of periconception pharmacologic HIV risk-reduction requires an understanding of the links between pregnancy and adherence to this prevention strategy. METHODS: We assessed study gel adherence among women with pregnancies compared to women without pregnancies enrolled in the CAPRISA 004 phase IIB trial of 1% vaginal tenofovir gel. Pregnancy was assessed with monthly urine tests. Adherence was measured monthly and defined as proportion of sex acts covered by two returned, used applicators based on pre- and post-coital dosing. High adherence was defined as a median adherence score of >80%, that is, more than 80% of sex acts were covered by two applications of study gel. A multivariate generalized estimating equations (GEE) model with a binomial distribution was used to assess covariates associated with high adherence (>80%) over time. Median adherence before and after pregnancy was compared using Wilcoxon signed rank test. RESULTS: Among 868 women, 53 had at least 1 pregnancy (4.06 per 100 woman years, 95% CI: 3.04, 5.31). Women with pregnancies had lower median adherence compared to women without pregnancies (50% [IQR: 45–83] vs. 60% [IQR: 50–100], p = 0.02). Women with pregnancies also had a 48% lower odds of high adherence compared to women without pregnancies when adjusting for confounders (aOR 0.52, 95%CI: 0.41–0.66, p<0.0001). Among women with pregnancies, adherence before and after pregnancy was not different (50% [IQR: 46–83] vs. 55% [IQR: 20–100], p = 0.68). CONCLUSIONS: Women with pregnancies were less likely to have high adherence to study gel compared to women without pregnancies. Understanding these differences may inform findings from HIV prevention trials and future implementation of antiretroviral prophylaxis for at-risk women who choose to conceive. The protocol for the parent trial is registered on ClinicalTrials.gov, NCT00441298, http://www.clinicaltrials.gov/ct2/show/NCT00441298.
format Online
Article
Text
id pubmed-3589407
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-35894072013-03-07 Women with Pregnancies Had Lower Adherence to 1% Tenofovir Vaginal Gel as HIV Preexposure Prophylaxis in CAPRISA 004, a Phase IIB Randomized-Controlled Trial Matthews, Lynn T. Sibeko, Sengeziwe Mansoor, Leila E. Yende-Zuma, Nonhlanhla Bangsberg, David R. Karim, Quarraisha Abdool PLoS One Research Article BACKGROUND: Antiretroviral prophylaxis may be a critical strategy to reduce periconception HIV transmission. Maximizing the benefit of periconception pharmacologic HIV risk-reduction requires an understanding of the links between pregnancy and adherence to this prevention strategy. METHODS: We assessed study gel adherence among women with pregnancies compared to women without pregnancies enrolled in the CAPRISA 004 phase IIB trial of 1% vaginal tenofovir gel. Pregnancy was assessed with monthly urine tests. Adherence was measured monthly and defined as proportion of sex acts covered by two returned, used applicators based on pre- and post-coital dosing. High adherence was defined as a median adherence score of >80%, that is, more than 80% of sex acts were covered by two applications of study gel. A multivariate generalized estimating equations (GEE) model with a binomial distribution was used to assess covariates associated with high adherence (>80%) over time. Median adherence before and after pregnancy was compared using Wilcoxon signed rank test. RESULTS: Among 868 women, 53 had at least 1 pregnancy (4.06 per 100 woman years, 95% CI: 3.04, 5.31). Women with pregnancies had lower median adherence compared to women without pregnancies (50% [IQR: 45–83] vs. 60% [IQR: 50–100], p = 0.02). Women with pregnancies also had a 48% lower odds of high adherence compared to women without pregnancies when adjusting for confounders (aOR 0.52, 95%CI: 0.41–0.66, p<0.0001). Among women with pregnancies, adherence before and after pregnancy was not different (50% [IQR: 46–83] vs. 55% [IQR: 20–100], p = 0.68). CONCLUSIONS: Women with pregnancies were less likely to have high adherence to study gel compared to women without pregnancies. Understanding these differences may inform findings from HIV prevention trials and future implementation of antiretroviral prophylaxis for at-risk women who choose to conceive. The protocol for the parent trial is registered on ClinicalTrials.gov, NCT00441298, http://www.clinicaltrials.gov/ct2/show/NCT00441298. Public Library of Science 2013-03-05 /pmc/articles/PMC3589407/ /pubmed/23472071 http://dx.doi.org/10.1371/journal.pone.0056400 Text en © 2013 Matthews et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Matthews, Lynn T.
Sibeko, Sengeziwe
Mansoor, Leila E.
Yende-Zuma, Nonhlanhla
Bangsberg, David R.
Karim, Quarraisha Abdool
Women with Pregnancies Had Lower Adherence to 1% Tenofovir Vaginal Gel as HIV Preexposure Prophylaxis in CAPRISA 004, a Phase IIB Randomized-Controlled Trial
title Women with Pregnancies Had Lower Adherence to 1% Tenofovir Vaginal Gel as HIV Preexposure Prophylaxis in CAPRISA 004, a Phase IIB Randomized-Controlled Trial
title_full Women with Pregnancies Had Lower Adherence to 1% Tenofovir Vaginal Gel as HIV Preexposure Prophylaxis in CAPRISA 004, a Phase IIB Randomized-Controlled Trial
title_fullStr Women with Pregnancies Had Lower Adherence to 1% Tenofovir Vaginal Gel as HIV Preexposure Prophylaxis in CAPRISA 004, a Phase IIB Randomized-Controlled Trial
title_full_unstemmed Women with Pregnancies Had Lower Adherence to 1% Tenofovir Vaginal Gel as HIV Preexposure Prophylaxis in CAPRISA 004, a Phase IIB Randomized-Controlled Trial
title_short Women with Pregnancies Had Lower Adherence to 1% Tenofovir Vaginal Gel as HIV Preexposure Prophylaxis in CAPRISA 004, a Phase IIB Randomized-Controlled Trial
title_sort women with pregnancies had lower adherence to 1% tenofovir vaginal gel as hiv preexposure prophylaxis in caprisa 004, a phase iib randomized-controlled trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3589407/
https://www.ncbi.nlm.nih.gov/pubmed/23472071
http://dx.doi.org/10.1371/journal.pone.0056400
work_keys_str_mv AT matthewslynnt womenwithpregnancieshadloweradherenceto1tenofovirvaginalgelashivpreexposureprophylaxisincaprisa004aphaseiibrandomizedcontrolledtrial
AT sibekosengeziwe womenwithpregnancieshadloweradherenceto1tenofovirvaginalgelashivpreexposureprophylaxisincaprisa004aphaseiibrandomizedcontrolledtrial
AT mansoorleilae womenwithpregnancieshadloweradherenceto1tenofovirvaginalgelashivpreexposureprophylaxisincaprisa004aphaseiibrandomizedcontrolledtrial
AT yendezumanonhlanhla womenwithpregnancieshadloweradherenceto1tenofovirvaginalgelashivpreexposureprophylaxisincaprisa004aphaseiibrandomizedcontrolledtrial
AT bangsbergdavidr womenwithpregnancieshadloweradherenceto1tenofovirvaginalgelashivpreexposureprophylaxisincaprisa004aphaseiibrandomizedcontrolledtrial
AT karimquarraishaabdool womenwithpregnancieshadloweradherenceto1tenofovirvaginalgelashivpreexposureprophylaxisincaprisa004aphaseiibrandomizedcontrolledtrial